Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343678 | 1.00 | CYP2D6 (0.55) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL3682214 | 1.00 | CYP2D6 (0.55) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL344762 | 0.91 | CTSK (0.48) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL2018992 | 0.91 | CTSK (0.48) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL344763 | 0.91 | CTSK (0.48) | CYP2D6CTSKCTSSPPARAPPARG | |
| Hydrochloric Acid SCHEMBL25223717 | 0.90 | CTSK (0.47) | CYP2D6CTSKCTSSPPARAPPARG | |
| Hydrochloric Acid SCHEMBL25223716 | 0.90 | CTSK (0.47) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL1486220 | 0.87 | CTSS (0.50) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL3323682 | 0.87 | CTSS (0.50) | CYP2D6CTSKCTSSPPARAPPARG | |
| SCHEMBL688341 | 0.87 | CTSS (0.50) | CYP2D6CTSKCTSSPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010782-A | Gelagliptin intermediate Process for the preparation of bulk compounds | 四川定科制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-117682981-A | Preparation method of gemagliptin prodrug | 中国科学院大连化学物理研究所 | 2024-03-12 | — | — | CN | claimed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | claimed |
| CN-104593173-A | Detergent for grapes | YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | claimed |
| CN-122010782-A | Gelagliptin intermediate Process for the preparation of bulk compounds | 四川定科制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010782-A | Gelagliptin intermediate Process for the preparation of bulk compounds | 四川定科制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | CLEVELAND CLINIC FOUND (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250136563-A1 | THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR | BETAGENON AB (SE) | 2025-05-01 | — | — | US | disclosed |
| CN-119841819-A | Degradation agent for targeting BCR-ABL and application thereof | 北京大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | CYP2D6 2451/4885CTSK 894/4885CTSS 796/4885 |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | SLC6A6, BHMT2, BHMT | CYP2D6 642/4885CTSK 3175/4885CTSS 3769/4885 |
| US-20250136563-A1 | THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR | PRKAB1, PRKAG1, PRKAA1 | CYP2D6 1841/4885CTSK 2422/4885CTSS 4104/4885 |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | CYP2D6 826/4885CTSK 3459/4885CTSS 2668/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | CYP2D6 2010/4885CTSK 1001/4885CTSS 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.